Lancet HIV

TES-STUDY-P016

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV. 2019. DOI: 10.1016/S2352-3018(19)30338-8. PMID: 31611038. NCT02196831. https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288

Study design

Record details

Design: Human clinical and physiological evidence

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P016Human clinical and physiological evidence

Lancet HIV

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV. 2019. DOI: 10.1016/S2352-3018(19)30338-8. PMID: 31611038. NCT02196831. https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/(2019). DOI: 10.1016/S2352-3018(19